Chronic constipation

AE Bharucha, A Wald - Mayo Clinic Proceedings, 2019 - Elsevier
AE Bharucha, A Wald
Mayo Clinic Proceedings, 2019Elsevier
Constipation is a common symptom that may be primary (idiopathic or functional) or
associated with a number of disorders or medications. Although most constipation is self-
managed by patients, 22% seek health care, mostly to primary care physicians (> 50%) and
gastroenterologists (14%), resulting in large expenditures for diagnostic testing and
treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal
secretagogues, and peripherally restricted μ-opiate antagonists are effective and safe; the …
Abstract
Constipation is a common symptom that may be primary (idiopathic or functional) or associated with a number of disorders or medications. Although most constipation is self-managed by patients, 22% seek health care, mostly to primary care physicians (>50%) and gastroenterologists (14%), resulting in large expenditures for diagnostic testing and treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal secretagogues, and peripherally restricted μ-opiate antagonists are effective and safe; the lattermost drugs are a major advance for managing opioid-induced constipation. Constipation that is refractory to available laxatives should be evaluated for defecatory disorders and slow-transit constipation using studies of anorectal function and colonic transit. Defecatory disorders are often responsive to biofeedback therapies, whereas slow-transit constipation may require surgical intervention in selected patients. Both efficacy and cost should guide the choice of treatment for functional constipation and opiate-induced constipation. Currently, no studies have compared inexpensive laxatives with newer drugs that work by other mechanisms.
Elsevier